文献速递乳腺癌

低剂量他莫昔芬预防乳腺上皮内瘤变局部及对侧复发的随机安慰剂对照试验

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
PubMed 文献 · J Clin Oncol · 2019-04-11

这项多中心随机安慰剂对照试验纳入500例激素敏感或未知的乳腺上皮内瘤变女性,术后分别接受他莫昔芬5 mg/d或安慰剂治疗3年。中位随访5.1年,他莫昔芬组14例肿瘤事件 vs 安慰剂组28例(HR 0.48,95%CI 0.26-0.92,P=0.02),对侧乳腺事件减少75%(3 vs 12,HR 0.25,95%CI 0.07-0.88,P=0.02)。结论认为他莫昔芬5 mg/d用3年可使复发减半且毒性有限,为这类疾病提供新治疗选择。

要点

  • 他莫昔芬5 mg/d用3年使乳腺上皮内瘤变复发风险降低约一半(HR 0.48,95%CI 0.26-0.92,P=0.02)。
  • 对侧乳腺事件减少75%(3 vs 12,HR 0.25,95%CI 0.07-0.88,P=0.02)。
  • 除每日潮热频率轻度增加(P=0.02)外,患者报告结局两组无差异。

核心结论

  • 他莫昔芬5 mg/d用3年可使乳腺上皮内瘤变复发减半且毒性有限,为这类疾病提供新治疗选择。

研究设计与样本

  • 多中心随机安慰剂对照试验,纳入500例75岁及以下激素敏感或未知的乳腺上皮内瘤变女性,术后接受他莫昔芬5 mg/d或安慰剂治疗3年。
  • 主要终点为浸润性乳腺癌或导管原位癌的发生率。

主要发现

  • 中位随访5.1年(四分位距3.9-6.3年),他莫昔芬组14例肿瘤事件 vs 安慰剂组28例(11.6 vs 23.9/1000人年;HR 0.48;95%CI 0.26-0.92;P=0.02),5年需治疗人数为22(95%CI 20-27)。
  • 他莫昔芬使对侧乳腺事件减少75%(3 vs 12例;HR 0.25;95%CI 0.07-0.88;P=0.02)。
  • 患者报告结局除他莫昔芬组每日潮热频率轻度增加外(P=0.02),两组无差异。
  • 严重不良事件他莫昔芬组12例 vs 安慰剂组16例,包括他莫昔芬组1例深静脉血栓和1例I期子宫内膜癌,安慰剂组1例肺栓塞。

关键数值与推荐

  • 他莫昔芬5 mg/d,术后口服3年。
  • 主要终点为浸润性乳腺癌或导管原位癌的发生率。

临床怎么用

  • 作者结论认为他莫昔芬5 mg/d用3年可使乳腺上皮内瘤变复发减半且毒性有限,为这类疾病提供新治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for a shorter period could be as effective in preventing recurrence from breast intraepithelial neoplasia but have a lower toxicity than the standard dose. PATIENTS AND METHODS: We conducted a multicenter randomized trial of tamoxifen, 5 mg/d or placebo administered for 3 years after surgery in women with hormone-sensitive or unknown breast intraepithelial neoplasia, including atypical ductal hyperplasia and lobular or ductal carcinoma in situ. The primary end point was the incidence of invasive breast cancer or ductal carcinoma in situ. RESULTS: Five hundred women 75 years of age or younger were included. After a median follow-up of 5.1 years (interquartile range, 3.9-6.3 years), there were 14 neoplastic events with tamoxifen and 28 with placebo (11.6 v 23.9 per 1,000 person-years; hazard ratio, 0.48; 95% CI, 0.26 to 0.92; P = .02), which resulted in a 5-year number needed to treat of 22 (95% CI, 20 to 27). Tamoxifen decreased contralateral breast events by 75% (three v 12 events; hazard ratio, 0.25; 95% CI, 0.07 to 0.88; P = .02). Patient-reported outcomes were not different between arms except for a slight increase in frequency of daily hot flashes with tamoxifen (P = .02). There were 12 serious adverse events with tamoxifen and 16 with placebo, including one deep vein thrombosis and one stage I endometrial cancer with tamoxifen and one pulmonary embolism with placebo. CONCLUSION: Tamoxifen at 5 mg/d for 3 years can halve the recurrence of breast intraepithelial neoplasia with a limited toxicity, which provides a new treatment option in these disorders.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019. PMID: 30973790. doi:10.1200/JCO.18.01779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。